BRCA1 and pancreatic neoplasm: Moreover, treating pancreatic cancer cell lines MIA PaCa-2 and SW1990 with 25 μM of TAT-conjugated peptide (283–302) reduced BRCA1 expression and enhanced their sensitivity to olaparib compared to that of cells treated with a scrambled control peptide (Supplementary Fig. 8g,,  h).